0000000001030712

AUTHOR

Ac Frigo

showing 3 related works from this author

Intention-to-treat survival benefit of liver transplantation in patients with hepatocellular cancer

2017

The debate about the best approach to select patients with hepatocellular cancer (HCC) waiting for liver transplantation (LT) is still ongoing. This study aims to identify the best variables allowing to discriminate between "high-" and "low-benefit" patients. To do so, the concept of intention-to-treat (ITT) survival benefit of LT has been created. Data of 2,103 adult HCC patients consecutively enlisted during the period 1987-2015 were analyzed. Three rigorous statistical steps were used in order to create the ITT survival benefit of LT: the development of an ITT LT and a non-LT survival model, and the individual prediction of the ITT survival benefit of LT defined as the difference between…

Malemedicine.medical_specialtySettore MED/18 - CHIRURGIA GENERALEmedicine.medical_treatment030230 surgeryMilan criteriaLiver transplantation03 medical and health sciencesLiver disease0302 clinical medicineInternal medicinemedicineCarcinoma Hepatocellular; Europe; Female; Humans; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Liver Transplantation; HepatologyHumansRisk factorHepatology; hepatocellular cancer; liver transplantationCarcinoma Hepatocellular; Europe; Female; Humans; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Liver TransplantationSurvival analysisRetrospective StudiesIntention-to-treat analysisHepatologybusiness.industryCarcinomaLiver NeoplasmsRetrospective cohort studyHepatocellularHepatologyMiddle Agedmedicine.diseaseSurgeryLiver TransplantationSettore MED/18Europehepatocellular cancer030211 gastroenterology & hepatologyFemalebusiness
researchProduct

Relapse risk factors in anti-N-methyl-D-aspartate receptor encephalitis

2019

Aim: To identify factors that may predict and affect the risk of relapse in anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. Method: This was a retrospective study of an Italian cohort of patients with paediatric (≤18y) onset anti-NMDAR encephalitis. Results: Of the 62 children included (39 females; median age at onset 9y 10mo, range 1y 2mo–18y; onset between 2005 and 2018), 21 per cent relapsed (median two total events per relapsing patient, range 2–4). Time to first relapse was median 31.5 months (range 7–89mo). Severity at first relapse was lower than onset (median modified Rankin Scale [mRS] 3, range 2–4, vs median mRS 5, range 3–5; admission to intensive care unit: 0/10 vs 3/10…

Male030506 rehabilitationGastroenterologyCohort Studies0302 clinical medicineRetrospective StudieModified Rankin ScaleRecurrenceRisk FactorsChildrelapseAnti-N-Methyl-D-Aspartate Receptor EncephalitisHazard ratioItalyChild PreschoolCohortanti‐N‐methyl‐D‐aspartate receptor encephalitisFemale0305 other medical scienceEncephalitisHumanCohort studymedicine.medical_specialtyAdolescentSocio-culturaleanti-NMDAR antibodies03 medical and health sciencesanti-NMDARDevelopmental NeuroscienceInternal medicinemedicineAdolescent; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Child; Child Preschool; Cohort Studies; Female; Humans; Infant; Italy; Male; Recurrence; Retrospective Studies; Risk FactorsHumansPreschoolSurvival analysisRetrospective StudiesAutoimmune encephalitisbusiness.industryInfantRetrospective cohort studymedicine.diseaseanti-NMDAR antibodies autoimmune encephalitis anti‐N‐methyl‐D‐aspartate receptor encephalitisautoimmune encephalitisAnti-N-methyl-D-aspartate receptor encephalitis anti-NMDAR autoimmune encephalitis relapseAnti-N-Methyl-D-Aspartate Receptor EncephalitiPediatrics Perinatology and Child HealthNeurology (clinical)Cohort Studiebusiness030217 neurology & neurosurgery
researchProduct

Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study

2018

Prognostic assessment of patients with hepatocellular carcinoma (HCC) at the time of diagnosis remains controversial and becomes even more complex at the time of restaging when new variables need to be considered. The aim of the current study was to evaluate the prognostic utility of restaging patients before proceeding with additional therapies for HCC. Two independent Italian prospective databases were used to identify 1,196 (training cohort) and 648 (validation cohort) consecutive patients with HCC treated over the same study period (2008-2015) who had complete restaging before decisions about additional therapies. The performance of the Italian Liver Cancer (ITA.LI.CA) prognostic score …

MaleOncologyDatabases FactualLiver cancer; non surgical therapy; prognostic system; surgical therapy; survivalhepatocellular carcinoma stage treatmentKaplan-Meier EstimateCohort StudiesLiver disease0302 clinical medicineMiddle AgedSorafenibPrognosisItaly030220 oncology & carcinogenesisCatheter AblationDisease ProgressionFemale030211 gastroenterology & hepatologysurgical therapyLiver cancerLiver cancermedicine.drugCohort studySorafenibmedicine.medical_specialtyCarcinoma HepatocellularSettore MED/12 - GASTROENTEROLOGIAClinical Decision-MakingRisk AssessmentsurvivalDisease-Free SurvivalStatistics Nonparametric03 medical and health sciencesnon surgical therapyInternal medicinemedicineHepatectomyHumansInfusions Intra-ArterialNeoplasm InvasivenessSurvival analysisAgedNeoplasm StagingRetrospective StudiesAnalysis of VarianceHepatologybusiness.industryprognostic systemReproducibility of ResultsCancerRetrospective cohort studymedicine.diseaseSurvival AnalysisbusinessProgressive disease
researchProduct